Page 122 - Haematologica August 2018

M. Trnĕný et al.
phase II, single-arm, multicentre study of
coltuximab ravtansine (SAR3419) and rit- uximab in patients with relapsed or refrac- tory diffuse large B-cell lymphoma. Br J Haematol. 2016;173(5):722-730.
30. Jacobsen ED, Sharman JP, Oki Y, et al. Brentuximab vedotin demonstrates objec- tive responses in a phase 2 study of relapsed/refractory DLBCL with variable CD30 expression. Blood. 2015;125(9):1394- 1402.
31. Palanca-Wessels MC, Czuczman M, Salles G, et al. Safety and activity of the anti- CD79B antibody-drug conjugate pola- tuzumab vedotin in relapsed or refractory B-cell non-Hodgkin lymphoma and chronic lymphocytic leukaemia: a phase 1 study. Lancet Oncol. 2015;16(6):704-715.
32. Morschhauser F, Flinn I, Advani RH, et al. Preliminary results of a phase II random- ized study (ROMULUS) of polatuzumab vedotin (PoV) or pinatuzumab vedotin (PiV) plus rituximab (RTX) in patients (Pts) with relapsed/refractory (R/R) non- Hodgkin lymphoma (NHL). American
Society of Clinical Oncology (ASCO), Chicago, IL, USA, May 30-June 3, 2014. Abstract 8519.
33. Wagner-Johnston ND, Goy A, Rodriguez MA, et al. A phase 2 study of inotuzumab ozogamicin and rituximab, followed by autologous stem cell transplant in patients with relapsed/refractory diffuse large B-cell lymphoma. Leuk Lymphoma. 2015;56(10): 2863-2869.
34. Viardot A, Goebeler M, Hess G, et al. Treatment of relapsed/refractory diffuse large B-cell lymphoma with the bispecific T- cell engager (TiTE) antibody construct blina- tumomab: primary analysis results from an open-label, Phase 2 study. 56th Amercian Society of Hematology (ASH) Annual Meeting and Exposition, San Francisco, CA, USA, December 6-9, 2014. Abstract 4460.
35. Goswami T, Forero A, Hamadani M, et al. Phase I/II study of MEDI-551, a humanized monoclonal antibody targeting CD19, in subjects with relapsed or refractory advanced B-cell malignancies. American Society of Clinical Oncology (ASCO),
Chicago, IL, USA, June 1-5, 2012. Abstract
8065.
36. Jurczak W, Zinzani PL, Goy A, et al. Phase
IIa study of single-agents MOR208 in patients with relapsed or refractory B-cell non-Hodgkin’s lymphoma (NHL). ASCO Annual Meeting, Chicago, IL, USA, May 29-June 2, 2015. Abstract 8500.
37. Pettengell R, Coiffier B, Narayanan G, et al. Pixantrone dimaleate versus other chemotherapeutic agents as a single-agent salvage treatment in patients with relapsed or refractory aggressive non-Hodgkin lym- phoma: a phase 3, multicentre, open-label, randomised trial. Lancet Oncol. 2012;13(7): 696-706.
38. Shain KH, Dalton WS, Tao J. The tumor microenvironment shapes hallmarks of mature B-cell malignancies. Oncogene. 2015;34(36):4673-4682.
39. Pfeifer M, Zheng B, Erdmann T, et al. Anti- CD22 and anti-CD79B antibody drug con- jugates are active in different molecular dif- fuse large B-cell lymphoma subtypes. Leukemia. 2015;29(7):1578-1586.
1358
haematologica | 2018; 103(8)